Hair Loss on Tirzepatide: What the Evidence Actually Shows

What clinical trials actually recorded about hair loss

The most detailed picture comes from SURMOUNT-1, the pivotal 72-week trial published in the New England Journal of Medicine that underpins tirzepatide's UK licence for weight management. Alopecia (the clinical term covering hair shedding and thinning) was recorded as an adverse event in around 5–6% of participants taking the 15 mg dose, compared with roughly 1% on placebo. That gap is meaningful, and it is right to take it seriously.

What the data also show is that the rate of hair loss tracked closely with the rate of weight reduction. Participants losing the most weight, fastest, were disproportionately represented among those who reported shedding. That pattern is the clinical fingerprint of telogen effluvium: a temporary shift in the hair-growth cycle triggered by physiological stress, including calorie restriction and rapid body-weight change. The follicles are not damaged, they have simply paused. Most resume normal activity within three to six months without any change to treatment. If you want a deeper explanation of the mechanisms involved, our guide to whether tirzepatide can cause hair loss walks through the science in detail. You can also read more about the full range of tirzepatide side effects and how they compare in frequency.

The NHS medicines page for tirzepatide lists hair loss among uncommon side effects (meaning it affects fewer than 1 in 10 but more than 1 in 100 people) and describes it as a recognised but usually self-limiting reaction. It is not listed as a reason to stop treatment in the absence of other concerns.

Why the medicine is not the direct cause, and why that matters for how you respond

Understanding the mechanism changes what you do about it. If hair loss were a direct pharmacological effect of tirzepatide on follicles, the logical response might be to reduce the dose or stop. Because the evidence instead points to calorie deficit and the physiological stress of rapid weight loss, the response is different: support your body through the transition rather than abandon the treatment causing the loss.

Protein adequacy is the area with the most practical support. Hair is almost entirely keratin (a protein) and in a calorie-restricted phase, dietary protein can fall short. Clinical guidance on weight-loss medicines consistently highlights lifestyle changes alongside treatment, including meeting protein targets, as part of managing this kind of side effect. Hydration and micronutrient intake (iron, zinc, biotin, vitamin D) are also commonly discussed, and our dedicated page on how to stop hair loss on tirzepatide brings together the practical steps most supported by clinical evidence, though personalised advice from a prescriber or dietitian is more reliable than a shelf of supplements.

The shedding typically peaks around two to four months after the period of fastest weight loss, then slows. For many people, hair density returns to baseline (or close to it) while they remain on treatment, once the body adjusts to its new weight set-point.

Is this different from other weight-loss medicines or interventions?

No, and that context matters. Telogen effluvium after significant weight loss is documented across bariatric surgery, very-low-calorie diets, and other GLP-1 receptor agonist medicines. The side-effect profile of Mounjaro (tirzepatide's UK brand name) shares this pattern with semaglutide (Wegovy) and with non-medical weight-loss interventions that produce comparable rates of loss, and our page on Mounjaro hair loss covers how this plays out specifically for people taking that branded version.

Tirzepatide does tend to produce greater average weight reduction than semaglutide 2.4 mg, as the SURMOUNT-5 head-to-head trial demonstrated. Greater loss, sooner, may mean the telogen effluvium phase is more pronounced for some people. It is worth mentioning at your first review (or before starting if you have a personal or family history of significant hair loss) so your prescriber can factor it into the conversation. A quick check-in with the clinical team costs nothing; our support team is available seven days a week if a question comes up between planned reviews.

When to get medical help, and how to report what you experience

Most hair shedding associated with tirzepatide does not need urgent attention. It is the kind of thing worth mentioning at your next scheduled review rather than calling 111 about. There are situations, though, where it is worth acting sooner.

Seek medical advice promptly if: the shedding is sudden and severe rather than gradual; you notice patchy bald areas or complete loss in localised spots (which may suggest a different cause, such as alopecia areata); hair loss is accompanied by other symptoms such as fatigue, cold intolerance or significant mood changes (which could point to thyroid issues, sometimes unmasked by dietary change); or you are losing eyebrows, eyelashes or body hair, not just scalp hair. These patterns warrant investigation beyond what is expected from telogen effluvium.

You can also report side effects directly to the MHRA via the Yellow Card scheme. Patient reports feed into ongoing safety monitoring for tirzepatide, which carries a Black Triangle (▼) designation in the UK, meaning all adverse events are actively reviewed. It takes a few minutes and helps build the evidence base for everyone who follows. If you are considering starting treatment and want to talk through side effects including hair loss, our prescribers cover this as part of every consultation, you can check your eligibility and begin that conversation at no cost.